A chemical that has very potent bioactivity has been deemed not a risk to you. You apply what you learned in ETX10 and conclude this judgement is reasonable because (choose the best answer)

Question

BlackTom AI · Accepted Answer

We start by restating the scenario: a chemically potent in bioactivity is deemed not a risk to you, applying ETX10 concepts to judge why this is reasonable. 
Option 1: 'This chemical is not a hazard' — This conflates hazard with risk. A substance can be hazardous (intrinsically capable of causing harm) yet not pose a risk if exposure is absent or negligible. Therefore, labeling it simply as 'not a hazard' overlooks the exposure-context component critical to risk assessment. 
Option 2: 'You are not exposed to the chemical' — This would indeed support a conclusion of no risk, but it is a condition about exposure rather than the intrinsic properties or the dose-response relationship. The statement asserts exposure absence, which may not be justified in all real-world settings, so using this as the best justification under ETX10 is less robust than focusing on the dose window. 
Option 3: 'This chemical is not a risk to you' — This is a conclusion rather than a justification. It asserts safety without explaining the mechanism or data (e.g., exposure, dose, or therapeutic index). It risks circular reasoning and does not align with ETX10’s emphasis on quantifying risk through exposure and dose–response. 
Option 4: 'This chemical is found in the lithosphere' — This geographic or geologic fact has no direct bearing on risk assessment for an individual in ETX10; presence in the lithosphere does not address exposure, dose, or harmful effects for a person. 
Option 5: 'This chemical has a large therapeutic index' — This option ties the assessment to a classic pharmacology concept: a large therapeutic index indicates a wide margin between therapeutic (or effective) dose and toxic dose, reducing risk under typical exposure scenarios. This aligns with the ETX10 framework, which weighs dose, exposure, and effect size to determine safety. A large therapeutic index supports the view that even potent bioactivity may not translate into appreciable risk at expected exposure levels. 
Putting it together, the reasoning favors the fifth option as the best justification: a large therapeutic index implies a wide safety margin, making the conclusion of not being a risk to you reasonable within ETX10’s risk assessment approach.

ETX 010 001 SQ 2025 Final Exam

A chemical that has very potent bioactivity has been deemed not a risk to you. You apply what you learned in ETX10 and conclude this judgement is reasonable because (choose the best answer)

View Explanation

Log in for full answers

Similar Questions

Assume the excess lifetime cancer risk for a certain level of exposure to the chemical acrylamide is estimated to be 7.2 x 10-3. This risk is ____________________ generally accepted criteria for follow-up investigation or intervention.

The _ is a common metric for characterizing risk of non-cancer risk, while ______ is acommon meteric for characterizing cancer risk.

Which of the following is/are true about risk assessment?

What steps of risk assessment does not consider the level of exposure?

___________ refers to using statistical methods to estimate the degree of harm likely to be caused by a toxic compound or behavior.

What is the overall objective of a risk assessment?

More Practical Tools for Students Powered by AI Study Helper

Homework AI Solver

Stylized AI Paper Writer

Plagiarism Checker Assistant

Citation AI Academic Writing Tool

In-Class Translation Assistant

AI Note Generator

AI Quiz Answers

Past Exam Questions from University Test Bank

Smart Practice Assistant

Adaptive Practice

Making Your Study Simpler

ETX 010 001 SQ 2025 Final Exam

A chemical that has very potent bioactivity has been deemed not a risk to you. You apply what you learned in ETX10 and conclude this judgement is reasonable because (choose the best answer)

View Explanation

Log in for full answers

Similar Questions

Assume the excess lifetime cancer risk for a certain level of exposure to the chemical acrylamide is estimated to be 7.2 x 10-3. This risk is ____________________ generally accepted criteria for follow-up investigation or intervention.

The _________________ is a common metric for characterizing risk of non-cancer risk, while ______________________ is acommon meteric for characterizing cancer risk.

Which of the following is/are true about risk assessment?

What steps of risk assessment does not consider the level of exposure?

___________ refers to using statistical methods to estimate the degree of harm likely to be caused by a toxic compound or behavior.

What is the overall objective of a risk assessment?

More Practical Tools for Students Powered by AI Study Helper

Making Your Study Simpler

The _ is a common metric for characterizing risk of non-cancer risk, while ______ is acommon meteric for characterizing cancer risk.